Digital-first experimental approach to optimise drug formulations
Merck and XtalPi Inc. collaborate on an AI-powered technology platform to predict the crystal morphologies of diabetic medication metformin HCl, validated by wet-lab experiments conducted with Merck’s expertise, in a ‘digital-first’ approach to drug development and optimisation.
Merck and Chinese pharmaceutical technology company XtalPi Inc. have published a collaborative study that leverages Merck’s wet-lab experimental capabilities with computational workflows provided by XtalPi for advanced drug development and manufacturing.
XtalPi delivers AI-powered pharmaceutical technology platforms to bring drug discovery and development solutions to the global pharmaceutical industry. Their collaboration with Merck utilised their morphology prediction platform, a crystal morphology engineering screening approach, in combination with Merck’s experimental capabilities to examine how different polymer additives affected the crystal habit of diabetic medication metformin HCl. The custom-made force fields brought by XtalPi’s platform successfully predicted the influence of these polymer additives. The predictions were validated by Merck’s wet-lab experiments.
XtalPi’s Chief Scientific Officer Peiyu Zhang commented that “By integrating XtalPi’s molecular dynamic predictions with Merck’s experimental validation, we have taken a step towards the rational engineering of desirable crystal habits. We hope to continue improving this ‘dry and wet’ lab method with leading industry experts like Merck in the production of novel therapeutics worldwide.”
Traditionally, undesirable crystal morphologies were investigated with disruptive and expensive lab methods such as milling and micronization. The ability of AI technology to provide molecular dynamics simulations demonstrates how AI-predictive technology platforms can be integrated into the drug development process for drug formulation optimisation and bring enhanced crystallization experiment designs.
Jan Gerit Brandenburg, Merck’s Head of Digital Chemistry, added: “Our collaboration with XtalPi is transforming pharmaceutical development. By seamlessly incorporating computer simulations with our experimental formulation expertise in a ‘digital-first’ approach, we are boosting [the] drug development processes and positively impacting patients’ lives.”
Source: Merck and XtalPi Collaboration Optimizes Drug Formulations with AI-Powered Techniques [Accessed April 17, 2023] https://www.prnewswire.com/news-releases/merck--xtalpi-collaboration-optimizes-drug-formulations-with-ai-powered-techniques-301797593.html
Discover new thinking at CPHI Barcelona
Innovations come in limitless forms. At CPHI Barcelona, you can hear from – and meet – experts who are driving their businesses forward with new thinking and new processes. Make connections, be inspired and get a fresh perspective on the road ahead.
Your CPHI Barcelona pass gives you access to all conference sessions, including Formulating the Future, as well as the chance to connect in-person with the global pharma supply chain from 24-26 October, at Fira Barcelona Gran Via. Browse the agenda and secure your pass today!
Related News
-
News Ardena forms partnership with RiboPro to improve mRNA-based therapies
Ardena and RiboPro have formed an alliance to boost their respective skills in manufacturing and producing nanoparticle and mRNA-based therapeutics to improve accessibility to this technology in the biotherapeutic landscape. -
News Updated: Samsung Biologics to manufacture Pfizer's biosimilars products
Samsung Biologics agrees to use their biocampus Plant 4 for the manufacture of a line of products from Pfizer. -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Soft capsule technology: modified pea starch as a vegetal origin alternative to gelatin in capsule shell
The latest soft capsule technology from Roquette using modified pea starch as an alternative to gelatin. -
News Your Prescription for Marketing Success: Digital Pharma Marketing Toolkit – Free eBook
Download your FREE pharma marketing eBook to learn why it is so important for pharmaceutical marketeers to develop their digital content marketing strategies in order to establish their companies as thought leaders and industry experts. -
News High demand: Vetter expands production capacities and services offered at its Austrian site
Pharma service provider further expands offerings for clinical development and manufacturing -
News Novavax will provide adjuvant Matrix-M for vaccine research with 3-year partnership
Novavax, developers behind the Matrix-M adjuvant, have entered into an agreement with the Bill and Melinda Gates Medical Research Institute to provide the adjuvant in preclinical vaccine research.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance